Pharmaceutical News RSS Feed - Pharmaceutical News

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease. [More]
FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). [More]
Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal. [More]
Volatile anesthetics may combat viral and bacterial infections in the lung

Volatile anesthetics may combat viral and bacterial infections in the lung

In use for more than a century, inhaled anesthetics like nitrous oxide and halothane have made modern surgery possible. Now, in experiments in mice, researchers at Johns Hopkins and elsewhere have added to evidence that certain so-called "volatile" anesthetics -- commonly used during surgeries -- may also possess powerful effects on the immune system that can combat viral and bacterial infections in the lung, including influenza and pneumonia. [More]
Common antidepressant can help stroke patients improve movement and coordination

Common antidepressant can help stroke patients improve movement and coordination

Working with mice, researchers at Johns Hopkins have added to evidence that a commonly prescribed antidepressant called fluoxetine helps stroke victims improve movement and coordination, and possibly why. [More]
Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Here's another discovery to bolster the case for medical marijuana: New research in mice suggests that THC, the active ingredient in marijuana, may delay the rejection of incompatible organs. [More]
Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA. [More]
Familial hypercholesterolemia patients can benefit from alirocumab drug

Familial hypercholesterolemia patients can benefit from alirocumab drug

Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials presented at ESC Congress today. [More]
Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's portfolio of NaP2b inhibitors effective September 30, 2015. [More]
Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress. [More]
North Shore-LIJ researcher compares safety benefits two blood-thinning medications

North Shore-LIJ researcher compares safety benefits two blood-thinning medications

A large, ambitious contrast of blood-thinning medications used during cardiac stent placement suggests that a very expensive drug offers no clear safety benefits over a much more affordable option, according to a prominent North Shore-LIJ researcher and cardiologist. [More]
Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. [More]
Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP]. [More]
IV drug abusers who undergo infective endocarditis surgery face higher risk of reoperation or death

IV drug abusers who undergo infective endocarditis surgery face higher risk of reoperation or death

Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery. [More]
Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins are associated with a 17% reduction in cardiac complications and a 43% reduction in mortality after noncardiac surgery, according to results from the VISION Study presented for the first time today at ESC Congress by Dr Otavio Berwanger, director of the Research Institute HCor, Hospital do Coração (Heart Hospital) in São Paulo, Brazil. [More]
Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show. [More]
AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, ("APIs"). [More]
LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

The combination drug valsartan/sacubitril known as LCZ696 significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker (ARB) olmesartan in patients with hypertension, according to results of the PARAMETER study. [More]
Educational program does not influence patients’ adherence to apixaban anticoagulant

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show. [More]
TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows. [More]
Advertisement
Advertisement